Use of materials for treatment of central nervous system lesions

Abstract

Disclosed are methods and materials for treatment of central nervous system lesions. Preferred methods and materials comprise neuronal precursor cells and/or marrow adherent stem cell-derived neuronal cells.

1 . A method comprising: 
 providing neuronal precursor cells; and    administering the neuronal precursor cells to a patient suffering from a central nervous system lesion in an amount sufficient to facilitate functional recovery of the patient.    
     
     
         2 . The method of  claim 1 , wherein the neuronal precursor cells are administered locally.  
     
     
         3 . The method of  claim 2 , wherein the neuronal precursor cells are administered to a central nervous system lesion of the patient.  
     
     
         4 . The method of  claim 1 , wherein the neuronal precursor cells are administered intraparenchymally.  
     
     
         5 . The method of  claim 1 , wherein the neuronal precursor cells comprise human neuronal precursor cells.  
     
     
         6 . The method of  claim 1 , wherein providing neuronal precursor cells comprises: 
 providing marrow adherent stem cells;    transdifferentiating the marrow adherent stem cells into neuronal precursor cells.    
     
     
         7 . The method of  claim 1 , wherein the central nervous system lesion is caused by ischemic stroke or hemorrhagic stroke.  
     
     
         8 . The method of  claim 1 , further comprising 
 allowing the neuronal precursor cells to migrate from a site of administration to other locations in the patient.    
     
     
         9 . The method of  claim 8 , wherein another location in the patient comprises a central nervous system lesion.  
     
     
         10 . The method of  claim 1 , further comprising 
 administering an immunosuppressive agent to the patient.    
     
     
         11 . The method of  claim 1 , wherein the functional recovery is a partial functional recovery.  
     
     
         12 . The method of  claim 1 , wherein the neuronal precursor cells are allogeneic with respect to the patient.  
     
     
         13 . A graft forming unit comprising: 
 neuronal precursor cells present in an amount sufficient to facilitate functional recovery of a patient suffering from a central nervous system lesion following administration of the neuronal precursor cells to the patient; and    a pharmaceutically acceptable carrier.    
     
     
         14 . The graft forming unit of  claim 13 , wherein the pharmaceutically acceptable carrier comprises a solvent, a dispersion media, an antibacterial agents, or an antifungal agent.  
     
     
         15 . The graft forming unit of  claim 13 , wherein the graft comprises neuronal precursor cells in an amount ranging from about 10,000 to about 100 million neuronal precursor cells.  
     
     
         16 . The graft forming unit of  claim 13 , wherein the neuronal precursor cells comprise a label.  
     
     
         17 . The graft forming unit of  claim 13 , wherein the neuronal precursor cells comprise human neuronal precursor cells.  
     
     
         18 . A method comprising: 
 providing marrow-adherent stem cell-derived neuronal cells; and    administering the marrow-adherent stem cell-derived neuronal cells to a patient suffering from a central nervous system lesion in an amount sufficient to facilitate functional recovery of the patient.    
     
     
         19 . The method of  claim 18 , wherein the marrow-adherent stem cell-derived neuronal cells are administered locally.  
     
     
         20 . The method of  claim 19 , wherein the marrow-adherent stem cell-derived neuronal cells are administered to a central nervous system lesion of the patient.  
     
     
         21 . The method of  claim 18 , wherein the marrow-adherent stem cell-derived neuronal cells are administered intraparenchymally.  
     
     
         22 . The method of  claim 18 , wherein the marrow-adherent stem cell-derived neuronal cells comprise human marrow-adherent stem cell-derived neuronal cells.  
     
     
         23 . The method of  claim 18 , wherein providing marrow-adherent stem cell-derived neuronal cells comprises: 
 providing marrow adherent stem cells; and    inducing the marrow adherent stem cells to form marrow-adherent stem cell-derived neuronal cells.    
     
     
         24 . The method of  claim 23 , further comprising: 
 transdifferentiating the marrow adherent stem cells into neuronal precursor cells; and    inducing the neuronal precursor cells to form neuronal cells.    
     
     
         25 . The method of  claim 18 , wherein the central nervous system lesion is caused by ischemic stroke or hemorrhagic stroke.  
     
     
         26 . The method of  claim 18 , further comprising administering an immunosuppressive agent to the patient.  
     
     
         27 . The method of  claim 18 , wherein the functional recovery is a partial functional recovery.  
     
     
         28 . The method of  claim 18 , wherein the marrow-adherent stem cell-derived neuronal cells are allogeneic with respect to the patient.  
     
     
         29 . A graft forming unit comprising: 
 marrow-adherent stem cell-derived neuronal cells present in an amount sufficient to facilitate functional recovery of a patient suffering from a central nervous system lesion following administration of the marrow-adherent stem cell-derived neuronal cells to the patient; and    a pharmaceutically acceptable carrier.    
     
     
         30 . The graft forming unit of  claim 29 , wherein the pharmaceutically acceptable carrier comprises a solvent, a dispersion media, an antibacterial agents, or an antifungal agent.  
     
     
         31 . The graft forming unit of  claim 29 , wherein the graft comprises neuronal precursor cells in an amount ranging from about 10,000 to about 100 million neuronal precursor cells.  
     
     
         32 . The graft forming unit of  claim 29 , wherein the marrow-adherent stem cell-derived neuronal cells comprise a label.  
     
     
         33 . The graft forming unit of  claim 29 , wherein the marrow-adherent stem cell-derived neuronal cells comprise human marrow-adherent stem cell-derived neuronal cells.